DARE

Daré Bioscience, Inc.
CAPPED RATING

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Daré Bioscience, Inc. (DARE) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (D-). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
A-
Factor Score 3.9 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.4
EV / EBITDA -0.5
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -51.9%
Price Return 12M -62.2%
Catalyst Signal 0.00
Market Cap $13.6M
TTM Revenue $1.4M
Price / Sales 10.0
ROE N/A

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) A- (3.9) C+ (2.6) D- (0.9) C+ (2.6) C+ (2.6)
2026-11-04 B- (3.0) A- (3.9) C+ (2.6) D- (0.9) C+ (2.7) C+ (2.6)
2026-10-28 B- (3.0) A- (4.0) C+ (2.7) D- (1.0) C+ (2.7) C+ (2.7)
2026-10-21 B- (3.0) A (4.2) C+ (2.7) D- (1.0) C+ (2.6) C+ (2.7)
2026-10-14 B- (3.0) A (4.2) C+ (2.7) F (0.7) C+ (2.6) C+ (2.6)
Page 1 of 5